Writer: ARIANNE NARDO
Contact: TOM MOORE
8798 John Pappajohn Pavilion
Iowa City IA 52242
UI Cancer Center doctor elected to NSABP board to further
breast cancer research
IOWA CITY, Iowa -- Peter Jochimsen, M.D., University
of Iowa professor of surgery and director of surgical oncology at the UI Hospitals
and Clinics, has been elected to the National Surgical Adjuvant Breast and
Bowel Project (NSABP) Board of Directors.
Sponsored by the National Cancer Institute, the NSABP
is an organization of research professionals concerned with studying, educating
and developing clinical trials related to breast cancer.
Jochimsen said he does not view the appointment as
a personal achievement, but rather as recognition of the skilled teams of
breast cancer researchers at the UI Cancer Center.
"This is not an award to me," Jochimsen
said, "Its to the contributions made by the many departments and
Jochimsens nomination and election to the board
reflects the more than 35-year relationship the UI Hospitals and Clinics and
NSABP have shared through clinical trials, research and the understanding
of the natural history of breast cancer as well as patterns of intervention.
The UI Cancer Center has actively participated in NSABP-sponsored clinical
trials, such as the Breast Cancer Prevention Trial (BCPT). During the BCPT,
UI Cancer Center researchers, in conjunction with several other participants,
investigated the effectiveness of tamoxifen and determined that it was useful
in preventing breast cancer in women at high risk for the disease.
As a board member, Jochimsens role will be to
develop and evaluate studies that correlate with the NSABPs primary
focus in national cancer research. Jochimsen is intent on also maintaining
a strong local link by keeping Iowas cancer care issues in mind.
"What I hope is that we get Iowans to more actively
participate in the national agenda, rather than change the national agenda
to fit Iowa," Jochimsen said.
A NSABP principal investigator since 1977, Jochimsens
current project is the Study of Tamoxifen and Raloxifene (STAR). The study
will examine how raloxifene measures against tamoxifen in preventing breast
cancer. A total of 22,000 postmenopausal women nationwide with a high-risk
of breast cancer will participate in STAR. For more information about STAR,
call (319) 356-2778.